CareDx Reveals Inducement Grants in Accordance with Nasdaq Listing Rule 5635(c)(4)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 07 2025
0mins
Source: Businesswire
Inducement Grants Announcement: CareDx, Inc. announced the award of inducement grants to 49 new employees, totaling 113,250 restricted stock units (RSUs) as part of their employment acceptance on November 4, 2025.
Chief Medical Officer RSU Grant: Dr. Jeffrey Teuteberg, the newly appointed Chief Medical Officer, received 88,180 RSUs as an inducement for his acceptance of the position.
Vesting Schedule: The RSUs will vest over four years, with 25% vesting on the first anniversary and the remainder vesting quarterly thereafter, contingent on continued service.
Compliance with Nasdaq Rules: The RSU awards were made in accordance with the Company’s 2025 Inducement Equity Incentive Plan and comply with Nasdaq Listing Rule 5635(c)(4).
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CDNA is 18.00 USD with a low forecast of 18.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 20.460
Low
18.00
Averages
18.00
High
18.00
Current: 20.460
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx (CDNA) Reports Q4 Revenue of $108 Million, Up 25% YoY
- Significant Revenue Growth: CareDx reported preliminary Q4 revenue of approximately $108 million, reflecting a 25% year-over-year increase, indicating strong market performance that is likely to boost investor confidence.
- Testing Services Revenue Rise: Testing services revenue reached approximately $78 million, up 23% year-over-year, demonstrating ongoing growth in the company's core business and enhancing its competitive position.
- Increase in Testing Volume: The volume of testing services approximated 53,000, marking a 17% increase, which reflects rising customer demand and could drive future revenue growth.
- Optimistic 2025 Outlook: Preliminary projections for 2025 revenue stand at approximately $380 million, a 14% year-over-year increase, showcasing the company's confidence in future growth, particularly in the expansion of testing services.
Continue Reading
Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
- Investor Sentiment: January is typically a time of optimism for investors, reflecting a hopeful outlook for the year ahead.
- Corporate Challenges: Despite investor optimism, corporate America may face significant challenges that could impact performance and growth.
Continue Reading